ADVFN
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,240.96
      0.25%
      US Tech 100
      22,151.20
      0.26%
      Dow Jones
      44,328.00
      0.20%
      Brent Oil
      69.775
      0.17%
      Bitcoin
      109,176.00
      0.22%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Amarin Corporation PLC (AMRN)

      7. Amarin Corporation PLC (AMRN) News

      Amarin Corporation PLC

      Amarin Corporation PLC (AMRN)

      NASDAQ
      16.92
      0.09
      ( 0.53% )
      Updated: 10:45:12
      15 min delayed - Upgrade to Realtime

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      AMRN News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 30 2025
      AMRN (0.53%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 24 2025
      AMRN (0.53%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 07 2025
      AMRN (0.53%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 07 2025
      AMRN (0.53%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      April 29 2025
      AMRN (0.53%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      April 22 2025
      AMRN (0.53%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      April 22 2025
      AMRN (0.53%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      April 22 2025
      AMRN (0.53%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      April 22 2025
      AMRN (0.53%)

      AMRN Discussion

      View Posts
      lizzy241 lizzy241 10 minutes ago
      This is why we should never rely on Goldman's analyst research regarding AMRN.
      This is a perfect example as to why.
      🤣

      UBS Maintains Sell on IBM, Raises Price Target to $195

      IBM is currently $289.33.
      👍️0
      Number sleven Number sleven 3 hours ago
      RMB,
      https://www.seair.co.in/us-import/product-icosapent-ethyl.aspx
      None of the API is produced in the United States.
      Sleven,
      👍 1
      tke458 tke458 3 hours ago
      It always amazes me when people can't see their own mistakes or past their own biases. I've made too many to count but I do try and own them and (albeit imperfectly) try and learn from them 
      👍️0
      Lemmiwinks Lemmiwinks 12 hours ago
      You know that throat tightening feeling….followed by the extra moisture in your eyes….and then Bruce Willis detonates the bomb.

      Armageddon gets me every time.

      The dude in the beginning wanted to name the comet Dottie “ a lifesucking bitch”…after his wife…...I’m still in but I’d call her Amarin.
      👍️0
      rosemountbomber rosemountbomber 13 hours ago
      200% eh.  I am not fully versed on whether Amarin would be included but a number of posters here suggest NO contending that the API is from here.  Would be a good question for the company.  
      👍️0
      Number sleven Number sleven 14 hours ago
      Take, I think Steve has gone to ground.
      Sleven,
      👍️0
      Bullrunner2 Bullrunner2 15 hours ago
      I am taking 4 pills a day and on my 3rd month as a preventive maintenance.
      👍️ 1
      abka abka 17 hours ago
      If pharmacical import tariff is put in place, will amarin will be included in that tariff?
      👍️0
      Nukemtiltheyglow Nukemtiltheyglow 18 hours ago
      Reminds me of the movie with Jim Belushi, "Taking Care of Business."
      👍️0
      hayward hayward 19 hours ago
      Nukemtiltheyglow

      Going to the game on Thursday go cubbies !!!!!!!!

      Don't want to poke the bear but what do you have to say to this FFS ?

      AMRN appears to be in a strong bullish trend. Its 200-day moving average is upwards sloping and the MACD histogram is above 0. Comparative Relative Strength analysis shows that this issue is outperforming the S&P 500.

      Michael
      👍️0
      Nukemtiltheyglow Nukemtiltheyglow 19 hours ago
      That's what happens when you pick the wrong mushrooms. I had a Botanist tell me once that the DNA of a poisonous mushroom and a similar non-poisonous one is so close that it takes a trained person to decipher. I'll stick with Portobello and Button (Cremini) mushrooms. I have picked "Football" mushrooms once in the wild and they were very good.
      👍️0
      Nukemtiltheyglow Nukemtiltheyglow 19 hours ago
      How about them Cubbies? 2nd best record in the NL. Trade deadline draws near. The Cubs need pitching for sure. To make it to the "Big Show." At least we have Baseball to pass the time.
      👍️0
      marzan marzan 20 hours ago
      I know when I post here, the short thugs will short more and I can add more cheap shares into my treasure chest. Thank you shorts!
      👍️0
      marzan marzan 20 hours ago
      And I take V atleast morning one and evening one 2 capsules a day for the past 10+ years, non-stop. V helps. V is great! A good maintenance drug for sure; and I never had a heart pain; may be V is helping me big time, even though I have heart problems run in the family.
      👍️0
      marzan marzan 20 hours ago
      This time I am NOT going to fail; in fact, I never gave up this stock. I continue to hold and keep averaging it out whenever I can; and in the process, I feel so good that I now hold a very comfortable huge winning position compared to what Captain was holding at his initial times. Go AMRN!
      👍 1
      marzan marzan 20 hours ago
      We are AMRN veterans here Captain; I still hold a ton of shares.
      👍️0
      JRoon71 JRoon71 20 hours ago
      Capt, I thought my understanding from Raf was that Bloomberg actually wasn't providing that prescription data anymore (either IQVIA or Symphony?). Maybe I misunderstood his explanation.
      👍️0
      marzan marzan 20 hours ago
      Oh yea, it is RAF. My bad how comes I forgot his name. With all the PBMs now sell only brand V, we now need weekly script update; hope someone finds a way. Like you Captain, I believe in this EPA science and I believe Justice Prevails. Of course You were my influence into this stock. It’s all happening now. Finally!!!.
      👍 1
      lizzy241 lizzy241 20 hours ago
      Capt. Bloomberg service is very expensive. Maybe when AMRN goes to $50 it may be worth investing in the service?
      👍️0
      CaptBeer CaptBeer 20 hours ago
      RafunRafun aka RAF. He had a contact using the Bloomberg Terminal. We lost that contact in Dec 2023. Never to return. RAF is still out there not sure if he is still holding AMRN or not. 
      👍 1
      marzan marzan 21 hours ago
      Captain et al., I forgot the name who used to report the weekly prescription/pill count for us here. Where is he? We miss him big time. Can someone else restart that work??
      👍️0
      DAR53 DAR53 21 hours ago
      I just hate it when the kangaroo stands on his head at the ice line. I get so confused.
      👍️ 2 😆 1
      tke458 tke458 23 hours ago
      Depends on if the kangaroo flashes it's tail.....
      👍️0
      Denisk Denisk 24 hours ago
      AMRN flirting with the $17/$0.85 level today. Could we see $28-$22 by the end of September?
      👍️0
      tke458 tke458 1 day ago
      You passed. Board is super quiet
      👍️0
      Monk4444 Monk4444 1 day ago
      Test
      👍️0
      marzan marzan 2 days ago
      All judges unanimously enbanc sided with the appellate court 3 judge panel decision against Hikma. What more number of judges you want??
      👍 2
      JRoon71 JRoon71 2 days ago
      Sleven, I believe the court can provide tailored injunctive relief, by preventing further marketing of a product until/unless the label is modified.

      I am not saying it's a "label change" in the scientific sense. I am saying it's corrective measures on the language used.

      And I'm not saying this will happen. I'm just saying that there is a lot of discussion about how this case is open and shut, and Amarin can't possibly lose (or will not have "less serious" damages awarded). We've seen how anything can happen when you get a small panel of judges (or a jury).
      👍️0
      ramfan60 ramfan60 2 days ago
      A salad with accidentally picked toxic mushrooms........ genius! Need to call my mother in law.
      👍️0
      Number sleven Number sleven 2 days ago
      North, I'm not sure what you are trying to tell me. I understand that it is impermeable to gain an FDA label through fraud. I also understand that the agency has guidance that relates to this. I also don't think that FDA will take any action without being forced to by the courts.
      Sleven,
      👍️0
      north40000 north40000 2 days ago
      sleven, where do you think that FDA fraud guideline I referenced came from? FDA's creative imagination? Somewhere out in the boondocks? How about 18 U.S.C. 1001 and its predecessors? From questionable, fraudulent conduct of earlier generic companies? Better yet, how about Hazel-Atlas, its predecessors and followers as authority, even binding authority? As an extreme, what about that salad found (from an investigation) to contain deadly mushrooms that a woman is asserted to have served her in-laws this past week?
      👍️ 1
      Number sleven Number sleven 2 days ago
      RMB, I agree. I would expect no action from FDA. They have no concerns about the legality of their actions. Whole agency is run by non-binding guidelines.
      Sleven,
      👍️0
      rosemountbomber rosemountbomber 2 days ago
      Agree Sleven. My point was concerning the FDA taking action. 
      👍️0
      Number sleven Number sleven 2 days ago
      RMB, If you want to get a better understanding of how Amarin v Hikma is going to play out, read all of the filings from GSK v Teva. We have the same legal representation. That case is a road map. Use a combination theory, label plus inappropriate advertising, to get past the pleading stage. Then go after the validity of the label through expert testimony during the trial. North is correct that the court could invalidate the "skinny label" on the basis of fraud. That issue has not yet been presented.
      Sleven,
      👍️0
      Number sleven Number sleven 2 days ago
      BBI, It's an article about the legal situation. Generic drugs are usually available at a lower cost than the Brand product. Not so much in this case. If the formularies cover the generic at better reimbursement level, it does save the patient money. Those details aren't really the point of the article.
      Sleven,
      👍️0
      rosemountbomber rosemountbomber 2 days ago
      Most docs are ignorant to those facts. Remember that brilliant neurosurgeon who believes in some nonsensical things, showing his grasp of a number of scientific facts to be lacking.
      👍️0
      Birdbrain Ideas Birdbrain Ideas 2 days ago
      My problem with Crouch's piece is this line: "Doctors have a strong incentive to prescribe the generic version for the patented CV use due to significantly lower costs, leading to broader patient access."

      Is that true? I thought, at most, the generic product is 15 percent less expensive than Vascepa. In return for that discount, the customer gets an inferior product, right? Isn't it true that generics only have to be 80 percent or 85 percent of the brand product's quality? And, minus the patented protective coat that enables a Vascepa pill to last three years and never get smelly, the generic pill deteriorates faster.

      The "leading to broader patient access" line is silly too. Generic access hasn't led to stimulated sales at all. In fact, they've remained nearly at a standstill since Amarin stopped advertising.

      I'm I'm correct, I hope Amarin reaches out to Crouch and educates him about this. Misinformation and an inability to communicate well is a big part of Amarin's problems. That and lack of sales.
      👍️0
      marzan marzan 2 days ago
      Well, these hyenas are hunted down now, imo. Two violations: fraud in the court by cropping the table, and infringing into cardio label. They are caught now. Of course the PBMs are proactive now, imo, but may not be off the hook.
      👍 1
      rosemountbomber rosemountbomber 2 days ago
      But I think what is coming is from the courts and legal front and not the FDA. 
      As far as PBMs, their main interest is money, which of course could include consideration of ant legal danger they could be implicated in. 
      👍️0
      marzan marzan 2 days ago
      RMB, why the generics are pulling their generic V product or more factually why the PBMs are not listing the generic version in their formulary? Both sides, the PBMs and the generic makers know what is coming and is haunting them already, imo.
      👍 1
      Number sleven Number sleven 2 days ago
      North, Yes. The court can make a determination about the legality of FDA actions. They can declare a label unlawful. My point was that they don't have the authority to alter a label.
      Sleven,
      👍️0
      rosemountbomber rosemountbomber 2 days ago
      Marzan, I hesitate to chime in for two reasons (but it sounds like I will anyways). First your question was directed to JRoon and secondly what I might suggest would run counter to what North suggests, and I highly respect and value his knowledge, which is far greater than mine when it comes to these things. But let me throw out the thoughts that are bouncing in my head wrt this.

      The way I understand it, the FDA does definitely have the ability and power to withdraw ANDAs approvals. But to me it sounds like it is when they find fraudulent action and data with respect to the ANDA application. It appears that even in that situation some people are disappointed that the FDA seems to have a history of being very reticent to use its power in this regard. Here is a STAT article from a year ago where it is clear that fraudulent data was submitted to the FDA but the FDA is giving these companies (mostly Generics) a pass or extension to resubmit or whatever.

      https://www.statnews.com/2024/08/12/fda-withdraw-approval-400-plus-tainted-drugs/
      👍️0
      marzan marzan 2 days ago
      Jruin, what is your response to North’s view that FDA will pull the ANDA label from every generic that is enjoying now on the ground Amarin HTG patents were fraudulently invalidated?
      👍️0
      marzan marzan 2 days ago
      Wow North, great finding of CVS formulary exclusive to brand V, and great deduction of eventual FDA action against the fraudulent Hikma losing the business and hence the disappearance of generic V in the business of the rest of the generics as well. We should eventually see the share price goes to $520 which was the pre R/S high of $26 if I remember correct. Thanks for your continued presence here North, You are great!
      👍 3
      north40000 north40000 2 days ago
      "court can't mandate a label change."  But: 

      1) per Hazel-Atlas, 322 U.S. 238(1944)(the Court exercised its equitable power to order reversal of the judgment of the 3rd Circuit in light of fraud committed in connection with evidence that was relied on to support the opinion accompanying that judgment). Bottom line--Hartford Empire business disappeared to the extent it relied on fraudulently obtained/maintained patents responsible for or originating/forming/supporting that business and business model.

      2) FDA can withdraw approval of ANDA(s) and corresponding labels, per its unchallenged authority/power vested by FDA Compliance Policy Guide (CPG) 120.100, when FDA finds fraudulent actions by any company(s) that omitted material information accompanying its request for approval of those ANDAs/labels. Bottom line--generic company business will disappear to the extent it relied on fraudulent evidence to invalidate patents of competitors to subsequently obtain ANDAs and labels to originate/support their business. Dr. Reddy's icosapent ethyl product and label disappeared from CVS/Caremark formulary on or before July 1, 2025. Hikma's  and other generics'  products and labels must also have disappeared in like manner from CVS/Caremark formulary if, as noticed,  Vascepa from Amarin (website) is exclusive and only.on CVS/Caremark formulary. 
      👍️ 4
      Number sleven Number sleven 3 days ago
      JRoon, One more thing. The court can't mandate a label change. FDA is the only organization with that authority.
      Sleven,
      👍️0
      Number sleven Number sleven 3 days ago
      JRoon, So what you are saying is, if Amarin took Hikma and Dr. Reddy's to court for infringement, The ruling would only apply to the three parties named in the suit?
      Sleven,
      👍️0
      JRoon71 JRoon71 3 days ago
      Sleven, I'm not saying there's no overlap. There is. I agree with that. I'm saying, procedurally, that the court decision in Amarin vs. Hikma only binds Hikma, but cannot automatically enjoin the other generics. It would then require Amarin to sue them.

      Although, in the meantime, Amarin could pursue injunctions against the other generics, which I think they would have a very strong argument for, assuming the court agrees with the overlapping indication argument. Or, if the court rules in this way, I would think the generics would feel strong pressure to withdraw.

      We just have to hope that, if we win, the court rules in such a way that it puts substantial pressure on the other generics, and does not simply mandate "better labeling" (but allows them to continue marketing generic IPE).
      👍️0
      Number sleven Number sleven 4 days ago
      JRoon, You clearly don't understand the ruling in GSK v Teva. First explain how there is no overlap between the two Vascepa indications. If you can't, explain how that overlap wouldn't invalidate all generic "skinny labels".
      Sleven,
      👍️ 4
      JRoon71 JRoon71 4 days ago
      Sleven, it would not "invalidate every generic label" automatically, but it could cause some or all of them to voluntarily withdraw their use, OR, Amarin would need to sue them each individually. 
      It likely depends on the specific outcome of the trial, and what the language and judgement/damages are.
      If the judgement is essentially "fix your marketing language", then it's still open season for generics. If the judgement is far more harsh, then the other generics would likely voluntarily withdraw, as none of them have a huge financial incentive to continue selling Icosapent Ethyl.
      Let's also not forget that Hikma is still actively defending the suit, which means they still have a belief that they could win. We are all talking as if an Amarin win is fait accompli.
      👍️0

      Your Recent History

      NASDAQ
      AMRN
      Amarin
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads